PMC6275313_01
(A,B) represent PET-CT images of two different pelvic metastases in the radiation field. Upper panel of (A,B): PET/CT on 30Sep2015, before Promitil with radiotherapy. Lower panel of (A,B): PET/CT on 28Dec2016, 15 months after Promitil with radiotherapy. Axial CT (left panel), FDG PET (middle panel) and fused FDG PET/CT (right panel) images of two metastatic lesions. The intense pathological uptake in a left nodule anteriorly to the rectal anastomosis (A, arrows) and in a right para-rectal nodule (B, arrows) has completely resolved with therapy on both PET and CT, along a prolonged follow-up (A,B, lower panel). Note post radiation rectal wall thickening on post-therapy CT images.
fonc-08-00544-g0001.jpg
PMC6275313_01_fonc-08-00544-g0001.jpg
F1
The treatment resulted in significant pain relief, complete regression of affected nodes by FDG PET-CT (Figure 1) and a significant and durable drop of tumor marker levels (Figure 2).
Tumor marker response to Promitil with radiotherapy. Same patient as in Figure 1. Note the sustained decrease of CEA and Ca19-9 levels after chemo-radiotherapy.
fonc-08-00544-g0002.jpg
PMC6275313_01_fonc-08-00544-g0002.jpg
F2
The treatment resulted in significant pain relief, complete regression of affected nodes by FDG PET-CT (Figure 1) and a significant and durable drop of tumor marker levels (Figure 2).
PMC6275313_02
Axial CT (left panel), FDG PET (middle panel) and fused FDG PET/CT (right panel) images before Promitil with radiotherapy (A, 07Apr2016), 3 months after Promitil with radiotherapy (B, 04July2016), and on a recent re-evaluation 22 months later (C, 19Feb2018). Initial pre-therapy intense pathological uptake in two adjacent porto-caval lymph nodes (arrows) resolved after therapy, with significant interval reduction in lymph nodes dimensions.
fonc-08-00544-g0003.jpg
PMC6275313_02_fonc-08-00544-g0003.jpg
F3
He responded with a metabolic CR of the porto-caval hilar lymphadenopathy by FDG PET/CT (Figure 3).